Siemens Healthineers Shanghai Diagnostic Manufacturing Facility Goes Into Production

Siemens Laboratory Systems (Shanghai) Co., Ltd, the first diagnostic manufacturing and R&D facility of Siemens Healthineers in the Asia Pacific region, officially started production on June 5.

With a total investment of nearly RMB 3 billion and a floor area of 35,000 square metres, the Diagnostic Facility will produce a wide range of diagnostic reagents for cardiac, thyroid, sex hormone, and oncology, as well as calibrators, diluents and quality control products for immunodiagnostics, with an expected annual capacity of 600 million tests.

“‘Healthy China’ has become one of the core directions of Siemens Healthineers’ global future development,” said Elisabeth Staudinger, Member of the Board of Directors of Siemens Healthcare. “The commissioning of the new diagnostic facility will not only vividly illustrate Siemens Healthineers’ brand statement of ‘Innovation Realm, for Every Life’, but also reaffirm our long-term commitment to the growing Chinese healthcare market.”

The commissioning of the base will further enhance the advantages of Siemens Healthineers’ diagnostic reagents in terms of product validity, responsiveness and service capability, significantly shorten the physical distance between the domestic client and the production end and speed up the logistics, thus enhancing the responsiveness of Siemens Healthineers in the local market and the overall competitiveness of Siemens Healthcare’s laboratory diagnostic business in China.

The commissioning of the Shanghai Diagnostic Facility is an important step in the continued implementation of Siemens Healthineers’ “National Intelligence Innovation” strategy in China. When the facility is fully operational, approximately 90% of the immunological reagents sold in China will be domestically produced, thus enhancing the overall competitiveness of Siemens Healthineers’ laboratory diagnostic business. At present, Siemens Healthineers has developed and manufactured more than 90 products in China and is on track to “localize the entire product line”.